MX2022009052A - Compuestos y conjugados de estos. - Google Patents
Compuestos y conjugados de estos.Info
- Publication number
- MX2022009052A MX2022009052A MX2022009052A MX2022009052A MX2022009052A MX 2022009052 A MX2022009052 A MX 2022009052A MX 2022009052 A MX2022009052 A MX 2022009052A MX 2022009052 A MX2022009052 A MX 2022009052A MX 2022009052 A MX2022009052 A MX 2022009052A
- Authority
- MX
- Mexico
- Prior art keywords
- topoisomerase inhibitor
- conjugates
- compounds
- ligand unit
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964181P | 2020-01-22 | 2020-01-22 | |
| PCT/EP2021/051259 WO2021148500A1 (en) | 2020-01-22 | 2021-01-21 | Compounds and conjugates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009052A true MX2022009052A (es) | 2022-08-15 |
Family
ID=74494865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009052A MX2022009052A (es) | 2020-01-22 | 2021-01-21 | Compuestos y conjugados de estos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230097908A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4093439A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023511184A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220130749A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114980934A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021210570A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022014391A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3166732A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022009052A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021148500A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118414339A (zh) * | 2021-12-16 | 2024-07-30 | 迈威(上海)生物科技股份有限公司 | 一种喜树碱类化合物及其偶联物 |
| AU2023279443A1 (en) | 2022-06-03 | 2025-01-23 | Ube Corporation | Antibody-multidrug conjugate |
| CN115160403B (zh) * | 2022-07-05 | 2025-06-27 | 博石丰生命科技(南通)有限公司 | 特异性拓扑异构酶抑制剂和可用于抗体药物偶联物及其制备方法 |
| WO2026078165A1 (en) | 2024-10-10 | 2026-04-16 | Astrazeneca Ab | Conjugates comprising cleavable linkers |
| WO2026145631A1 (zh) * | 2024-12-31 | 2026-07-09 | 上海复宏汉霖生物技术股份有限公司 | 一种配体-药物偶联物及制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4939255A (en) * | 1987-06-24 | 1990-07-03 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic camptothecin derivatives |
| JP2540357B2 (ja) * | 1987-06-24 | 1996-10-02 | 第一製薬株式会社 | 六環性化合物 |
| JP3008226B2 (ja) * | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| DK1813614T3 (da) | 2006-01-25 | 2012-01-23 | Sanofi Sa | Cytotoksiske midler, der omfatter nye tomaymycinderivater |
| JP5394246B2 (ja) * | 2007-03-30 | 2014-01-22 | ジェネンテック, インコーポレイテッド | 抗体及びイムノコンジュゲートとこれらの使用方法 |
| PE20090245A1 (es) | 2007-05-08 | 2009-03-17 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos |
| BRPI0818780A2 (pt) | 2007-10-19 | 2015-04-22 | Genentech Inc | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos |
| EA201200486A1 (ru) * | 2009-09-15 | 2012-08-30 | Серулин Фарма Инк. | Лечение онкологических заболеваний |
| TWI871999B (zh) * | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| HUE067016T2 (hu) * | 2015-11-25 | 2024-09-28 | Ligachem Biosciences Inc | Önfeláldozó csoportokat tartalmazó konjugátumok és ezekkel kapcsolos eljárások |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| US20190367605A1 (en) | 2016-11-10 | 2019-12-05 | Medimmune, Llc | Binding Molecules Specific For ASCT2 And Uses Thereof |
| JP7244987B2 (ja) * | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | 多剤抗体薬物コンジュゲート |
| KR20200142525A (ko) * | 2018-04-05 | 2020-12-22 | 노파르티스 아게 | 암에 대한 삼중특이성 결합 분자 및 이의 용도 |
| EP3794042B1 (en) * | 2018-05-18 | 2024-03-27 | Daiichi Sankyo Co., Ltd. | Anti-muc1- exatecan antibody-drug conjugate |
| KR20240104214A (ko) * | 2019-03-29 | 2024-07-04 | 메디뮨 리미티드 | 화합물 및 이의 접합체 |
| CN110974975B (zh) * | 2019-12-12 | 2023-10-20 | 成都百利多特生物药业有限责任公司 | 一种快速释放的抗体药物偶联物 |
| US12605459B2 (en) * | 2020-07-13 | 2026-04-21 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| NL2026947B1 (en) * | 2020-11-20 | 2022-07-01 | Synaffix Bv | Tyrosine-based antibody conjugates |
-
2021
- 2021-01-21 US US17/759,083 patent/US20230097908A1/en not_active Abandoned
- 2021-01-21 EP EP21702596.4A patent/EP4093439A1/en not_active Withdrawn
- 2021-01-21 CA CA3166732A patent/CA3166732A1/en active Pending
- 2021-01-21 BR BR112022014391A patent/BR112022014391A2/pt not_active IP Right Cessation
- 2021-01-21 MX MX2022009052A patent/MX2022009052A/es unknown
- 2021-01-21 CN CN202180010092.XA patent/CN114980934A/zh active Pending
- 2021-01-21 KR KR1020227028552A patent/KR20220130749A/ko active Pending
- 2021-01-21 AU AU2021210570A patent/AU2021210570A1/en not_active Abandoned
- 2021-01-21 WO PCT/EP2021/051259 patent/WO2021148500A1/en not_active Ceased
- 2021-01-21 JP JP2022544413A patent/JP2023511184A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021210570A1 (en) | 2022-09-01 |
| KR20220130749A (ko) | 2022-09-27 |
| JP2023511184A (ja) | 2023-03-16 |
| EP4093439A1 (en) | 2022-11-30 |
| CA3166732A1 (en) | 2021-07-29 |
| CN114980934A (zh) | 2022-08-30 |
| WO2021148500A1 (en) | 2021-07-29 |
| US20230097908A1 (en) | 2023-03-30 |
| BR112022014391A2 (pt) | 2022-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021552363A1 (en) | Compounds and conjugates thereof | |
| CR20220393A (es) | Compuestos y conjugados de estos | |
| BR112022014391A2 (pt) | Compostos e conjugados dos mesmos | |
| MX2024005545A (es) | Conjugados que comprenden fosforo (v) y una fraccion molecular de camptotecina. | |
| MX2021015221A (es) | Compuestos de aminobenzazepina, inmunoconjugados y usos de estos. | |
| TN2010000149A1 (en) | Spiroheterocyclic pyrrolidine dione derivatives useful as pesticides | |
| MY197127A (en) | Pyrrolobenzodiazepine conjugates | |
| MX2025012396A (es) | Conjugados que comprenden enlazadores escindibles | |
| CA3010551A1 (en) | Pyrrolobenzodiazepine conjugates | |
| WO2008141044A3 (en) | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates | |
| DK1534342T3 (da) | Modificerede saccharider, konjugater deraf og fremstilling deraf | |
| MX2026001691A (es) | Conjugados que comprenden enlazadores escindibles | |
| WO2008096841A1 (ja) | 二量化シクロ誘導体 | |
| AUPP649498A0 (en) | Organoboron derivatives and coupling thereof | |
| DK1327146T3 (da) | Forbindelse med et forgrenet linkermolekyle | |
| WO2022094262A8 (en) | Fap-activated serum extended half-life therapeutic conjugates | |
| WO2024238872A3 (en) | Isoindolinone-glutarimide antibody conjugates, and uses thereof | |
| WO2022125891A3 (en) | Anti-cea immunoconjugates, and uses thereof | |
| TW200942520A (en) | Heteroannelated anthraquinone derivatives and the synthesis method thereof | |
| WO2007100563A3 (en) | Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates | |
| MX2023001679A (es) | Inmunoconjugados de pirazolazepina y usos de estos. | |
| WO2006032893A3 (en) | Trityl derivatives for enhancing mass spectrometry | |
| PL1646622T3 (pl) | Pochodne takryny jako inhibitory acetylocholinoesterazy | |
| MY125378A (en) | Pentacyclic taxan compound | |
| WO2022218970A3 (en) | Pyrrolobenzodiazepine conjugates |